Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase TAK1]
Substrate: SMAD3

Description: Mothers against decapentaplegic homolog 3 (SMAD 3) (Mothers againstDPP homolog 3) (Mad3) (hMAD-3) (JV15-2) (hSMAD3).

Synonyms: MADH3

Ensembl ID: ENSG00000166949

UniprotKB/SwissProt: SMAD3_HUMAN (P84022)

Function: Transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinase. SMAD3 is a receptor-regulated SMAD (R-SMAD) (By similarity).

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm (By similarity). Nucleus (By similarity). Note=In the cytoplasm in the absence of ligand. Migration to the nucleus when complexed with SMAD4 (By similarity).
PDB:1MHD
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of SMAD3

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1SMAD3SMAD3_HUMANT8SILPF T PPIVK 26.64%CDK2 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
2SMAD3SMAD3_HUMANT8SILPF T PPIVK 26.64%CDK2 Phospho.ELM 7.0  ViewAnalyzing
3SMAD3SMAD3_HUMANT8SILPF T PPIVK 26.64%CDK4 Phospho.ELM 7.0  ViewAnalyzing
4SMAD3SMAD3_HUMANT8SILPF T PPIVK 26.64%CDK4 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
5SMAD3SMAD3_HUMANT179SNIPE T PPPGY 35.42%Erk2 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
6SMAD3SMAD3_HUMANT179SNIPE T PPPGY 35.42%CDK2 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
7SMAD3SMAD3_HUMANT179SNIPE T PPPGY 35.42%CDK2 Phospho.ELM 7.0  ViewAnalyzing
8SMAD3SMAD3_HUMANT179SNIPE T PPPGY 35.42%CDK4 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
9SMAD3SMAD3_HUMANT179SNIPE T PPPGY 35.42%CDK4 Phospho.ELM 7.0  ViewAnalyzing
10SMAD3SMAD3_HUMANS204SMDAG S PNLSP 16.61%Erk2 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
11SMAD3SMAD3_HUMANS204SMDAG S PNLSP 16.61%Erk2(MAPK1) Phospho.ELM 7.0 ViewAnalyzing
12SMAD3SMAD3_HUMANS204SMDAG S PNLSP 16.61%CDK2 HPRD:04380(in vitro)  ViewAnalyzing
13SMAD3SMAD3_HUMANS204SMDAG S PNLSP 16.61%CDK4 HPRD:04380(in vitro)  ViewAnalyzing
14SMAD3SMAD3_HUMANS208GSPNL S PNPMS 29.30%Erk2 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
15SMAD3SMAD3_HUMANS208GSPNL S PNPMS 29.30%CDK4 HPRD:04380(in vitro)  ViewAnalyzing
16SMAD3SMAD3_HUMANS208GSPNL S PNPMS 29.30%Erk2(MAPK1) Phospho.ELM 7.0 ViewAnalyzing
17SMAD3SMAD3_HUMANS208GSPNL S PNPMS 29.30%p38a HPRD:04380(in vitro;in vivo)  ViewAnalyzing
18SMAD3SMAD3_HUMANS208GSPNL S PNPMS 29.30%CDK2 HPRD:04380(in vitro)  ViewAnalyzing
19SMAD3SMAD3_HUMANS213SPNPM S PAHNN 21.86%CDK2 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
20SMAD3SMAD3_HUMANS213SPNPM S PAHNN 21.86%CDK2 Phospho.ELM 7.0  ViewAnalyzing
21SMAD3SMAD3_HUMANS213SPNPM S PAHNN 21.86%CDK4 HPRD:04380(in vitro;in vivo)  ViewAnalyzing
22SMAD3SMAD3_HUMANS213SPNPM S PAHNN 21.86%Erk2 HPRD:04380(in vitro)  ViewAnalyzing
23SMAD3SMAD3_HUMANS213SPNPM S PAHNN 21.86%p38a HPRD:04380(in vitro;in vivo)  ViewAnalyzing
24SMAD3SMAD3_HUMANS213SPNPM S PAHNN 21.86%CDK4 Phospho.ELM 7.0  ViewAnalyzing
25SMAD3SMAD3_HUMANS422PSIRC S SVS 24.75%TAK1 HPRD:04380(in vitro)  ViewAnalyzing
26SMAD3SMAD3_HUMANS422PSIRC S SVS 24.75% Phospho.ELM 7.0View   
27SMAD3SMAD3_HUMANS423SIRCS S VS 29.97% Phospho.ELM 7.0View   
28SMAD3SMAD3_HUMANS423SIRCS S VS 29.97% Swiss-Prot 55.0 (Similarity)View   
29SMAD3SMAD3_HUMANS423SIRCS S VS 29.97%TAK1 HPRD:04380(in vitro)  ViewAnalyzing
30SMAD3SMAD3_HUMANS425RCSSV S  36.13%TAK1 HPRD:04380(in vitro)  ViewAnalyzing
31SMAD3SMAD3_HUMANS425RCSSV S  36.13% Swiss-Prot 55.0 (Similarity)View   
32SMAD3SMAD3_HUMANS425RCSSV S  36.13% Phospho.ELM 7.0View